

MEDIA INFORMATION
RELEASE: IMMEDIATE
DATE: 22 March 2005

CBIO SIGNS AGREEMENT WITH GRIFFITH UNIVERSITY
FOR PHASE IIa TRIAL IN MULTIPLE SCLEROSIS OF LEAD COMPOUND

CBio Limited has signed an agreement with Griffith University to undertake a Phase II clinical trial in multiple sclerosis with the Company's leading compound, Cpn10 a heat shock protein.

The clinical study will be based at Griffith University's Gold Coast campus under the direction of Dr Simon Broadley.

"Commencement of the Griffith University site is a significant next step in CBio's Phase II clinical research programme," Dr Wolf Hanisch, CBio's chief executive said.

Chief Scientific Officer of CBio, Dr Dennis Feeney said preparations for implementation of the study were 'well advanced', adding that the first site for this study had already commenced at Royal Adelaide Hospital.

"The early Phase II studies with Cpn 10 will examine a range of autoimmune inflammatory diseases. Study of multiple sclerosis is a very important part of the development of Cpn10 and we are hoping to recruit up to 25 patients in a relatively short period of time at the Griffith University site," he added.

Griffith University Deputy Vice Chancellor (Research) Professor Lesley Johnson commended the research collaboration.

"The clinical trial is one of the first to be conducted under the auspices of Griffith's new School of Medicine and it is very much in the spirit of the university's long-term commitment to seeking out innovative solutions to 21st century problems," she said.

This agreement with Griffith University to undertake this clinical trial in MS may pave the way for additional basic and clinical research relationships with the University in the future.

CBio Limited is an Australian headquartered biotechnology company dedicated to the development of heat shock proteins as therapeutics for autoimmune and inflammatory diseases.

Further information

Dr Dennis Feeney, CSO Tel: 07-32521022
Dr Wolf Hanisch CEO Tel: 07-32521022